Navigation Links
New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
Date:12/5/2011

PARSIPPANY, N.J., Dec. 5, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced new data gleaned from a national database of patients from 381 U.S. hospitals who underwent common hospital-based surgical procedures and received opioids for postsurgical pain management. The data demonstrate that opioid-related adverse events (ORAEs) are associated with more than a $1,000 increase in hospitalization cost and more than a day increase in length of hospital stay (LOS). These findings will be presented at 2 p.m. CST today during a poster session at the 2011 Midyear Clinical Meeting of the American Society of Health-Systems Pharmacists (ASHP) in New Orleans.

In this retrospective analysis, researchers utilized Premier's database, the nation's most comprehensive repository of clinical, financial and outcomes information, to identify adult patients who underwent common soft tissue and orthopedic surgical procedures and received opioids from September 2008 to August 2010. All opioids consumed were converted to morphine-equivalent doses. Approximately 20 percent of surgical patients—or roughly one in five—were identified as experiencing an ORAE.

Researchers compared the mean total hospitalization cost and LOS between those patients who experienced an ORAE and those patients who did not. Key findings included:

  • Patients experiencing an ORAE had a 1.1-day increase in mean LOS compared to patients who did not (P<0.0001). 
  • Patients experiencing an ORAE had a $1,028 mean increase from the baseline hospitalization cost compared to patients who did not (P<0.0001).   

"Opioids have long been associated with a range of unwanted side effects in postsurgical patients, from nausea, vomiting and constipation
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
2. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
3. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
4. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
5. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
6. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
7. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
10. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
(Date:1/14/2014)... , January 14, 2014 Equashield ... for hazardous drugs, today announced that it has ... straight year.   Equashield,s closed systems ... pharmacists, nurses and other medical professionals who prepare ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... Group -, BRISBANE, Calif., May 28 ... clinical trials program through the,initiation of an additional ... The trial will assess BSI-201, the first ADP-ribose ... for the treatment,of uterine carcinosarcoma or malignant mixed ...
... C and LymphoStat-B(R) for lupus on track for ... potential launch in 2010 -,- ABthrax(TM) for inhalation anthrax on track to begin delivery fall ... ... - GSK to advance darapladib to Phase 3 for atherosclerosis -, ROCKVILLE, ...
Cached Medicine Technology:BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11
(Date:4/24/2014)... scientists a better understanding of drug interactions, which are ... , When two or more medications are taken at ... effectiveness of the other. Similarly, one drug may ... are a major cause of illness and hospitalization. ... scope of drug studies in humans. Limits come ...
(Date:4/24/2014)... (April 24, 2014) - Contact lenses coated with an antimicrobial ... infections, reports a study in Optometry and Vision ... of Optometry . The journal is published by ... Kluwer Health . , Studies in animals and now humans ... antimicrobial peptide melimine, according to the new research by Debarun ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... behavior is linked to risk-taking, too, study finds, ... thrill-seeking behavior that makes people love skydiving, mountain-climbing ... an area of the brain that has been ... and Purdue University researchers studied volunteers who were ...
... LANSING, Mich. Women are 30 percent less likely ... can limit brain damage after a stroke, according to ... were presented Feb. 19 in San Diego at the ... and American Stroke Association. , Tissue plasminogen activator, or ...
... 19 Usinas,Siderurgicas de Minas Gerais S.A. - USIMINAS (OTC: USNZY; BOVESPA: USIM3,USIM5, USIM6; Latibex: ... USIMINAS Fourth Quarter 2008 Results Conference Call., ... the opening, ... 2009 at 10:00 AM EST in English, ...
... (Nasdaq: MYL ) today announced that its Vice ... NASDAQ Stock Market opening on Friday, Feb. 20 from 9:15 ... to celebrate the company,s switch from The New York Stock ... Dec. 29, 2008. The company is listed on the NASDAQ ...
... pancreatitis remains a disease with an unpredictable clinical ... the elevated intraabdominal pressure (IAP) after onset of ... is increasingly recognized as an important risk factor ... disease. However, It is still not clear whether ...
... Executives at Sage, an industry-,leading provider of ... records (EHR - http://tinyurl.com/ah9dgb ) system ... federally qualified,health centers, today joined with forward-looking ... the signing of the American,Reinvestment and Recovery ...
Cached Medicine News:Health News:Thrill-Seekers' Brains May Be Wired Differently 2Health News:Women less likely to receive critical care after a stroke, MSU researchers find 2Health News:Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Fourth Quarter 2008 Earnings Results Webcast 2Health News:Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell 2Health News:Should intra-abdominal pressure measurement be a routine for all pancreatitis patients? 2Health News:Electronic Health Records (EHR) 'Leap Forward' Thanks to American Reinvestment and Recovery Act 2Health News:Electronic Health Records (EHR) 'Leap Forward' Thanks to American Reinvestment and Recovery Act 3
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 6mm from tip. Tip ang...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: